Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8101 USD | -3.56% | -1.33% | +42.12% |
14/05 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
14/05 | Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.12% | 3.3Cr | |
+33.37% | 4.95TCr | |
+1.55% | 4.26TCr | |
+49.11% | 4.25TCr | |
-4.22% | 2.91TCr | |
+11.57% | 2.66TCr | |
-21.00% | 1.86TCr | |
+7.36% | 1.32TCr | |
+28.30% | 1.25TCr | |
+23.80% | 1.21TCr |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share